Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Mao, Chen ^a   Fu, Xiao Hong ^a   Yuan, Jin Qiu ^a   Yang, Zu Yao ^a   Huang, Ya Fang ^a   Ye, Qian Ling ^b   Wu, Xin Yin ^a   Hu, Xue Feng ^a   Zhai, Zhi Min ^b   Tang, Jin Ling ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; ANTINEOPLASTIC AGENT;

ACUTE MYELOID LEUKEMIA; ADULT; ADVERSE OUTCOME; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CHILD; CHILL; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FATIGUE; FEVER; HUMAN; HYPERSENSITIVITY; INFECTION; LEUKEMIA REMISSION; MAINTENANCE CHEMOTHERAPY; MALAISE; MYALGIA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RIGOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION; ADOLESCENT; AGED; FEMALE; INDUCTION CHEMOTHERAPY; INFANT; LEUKEMIA, MYELOID, ACUTE; MALE; META ANALYSIS; MIDDLE AGED; MORTALITY; NEWBORN; PRESCHOOL CHILD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; INFANT, NEWBORN; INTERLEUKIN-2; LEUKEMIA, MYELOID, ACUTE; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964694315     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010248.pub2     Document Type: Review

References (69)

1. Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mrózek K, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. Journal of Clinical Oncology 2008;26(30):4934-9.
2. Blaise D, Attal M, Reiffers J, Michallet M, Bellanger C, Pico J, et al. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. European Cytokine Network 2000;11(1):91-8.
3. Faber E, Indrak K, Mocikova K, Kuvikova A, Penska M, Krahulcova E, et al. Low-dose interleukin-2 in AML in first remission - A multicenter randomized study [abstract]. Blood 1997;90(Suppl 1):240.
4. Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, et al. Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. Cancer 2014;120(7):1010-7.
5. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116(9):1413-21.
6. Kolitz JE, Hars V, DeAngelo DJ, Allen SL, Shea TC, Vij R, et al. Phase III trial of immunotherapy with recombinant interleukin-2 (rIL-2) versus observation in patients [1]60 years with acute myeloid leukemia (AML) in first remission (CR1): preliminary results from Cancer and Leukemia Group B (CALGB) 19808 [abstract]. Blood 2007;110(11):157.
7. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated paediatric acute myeloid leukemia: a report from the children's oncology group. Blood 2008;111(3):1044-53.
8. Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, et al. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for paediatric acute myeloid leukemia. Pediatric Blood Cancer 2011;57(3):398-405.
9. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Tjoa T, et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. The Cancer Journal from Scientific American 2000;6:S39-44.
10. Liu XL, Zhu WS, Liu Z, Huang SJ, Li SH. The influence of combined treatment of Interleukin-2 and chemotherapy on T-lymphocyte subgroup in acute myeloid leukemia. Chinese Journal of Postgraduate Medicine 2011;34(19):32-3.
11. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. Journal of Clinical Oncology 2010;28(5):808-14.
12. Petit A, Ducassou S, Leblanc T, Pasquet M, Rousseau A, Ragu C, ect Relevance of a one-year maintenance therapy with interleukin-2 in the treatment of childhood acute myeloid leukemia: Results from the French multicenter, phase III, randomized controlled SFCE trial, ELAM02. Blood. Conference: 56th Annual Meeting of the American Society of Hematology, ASH 2014. San Francisco: American Society of Hematology, 6 Dec 2014.
13. Willemze R, Suciu S, Mandelli F, Halkes SJM. Value of low dose IL-2 as maintenance following consolidation treatment or autologous transplantation in acute myelogenous leukemia (AML) patients aged 15-60 years who reached CR after high dose (HD-AraC) vs standard dose (SD-AraC) cytosine arabinoside during induction: Results of the AML-12 trial of EORTC and GIMEMA leukemia groups. American Society of Hematology 2009;114(22):791.
14. Willemze R, Suciu S, Mandelli F, Halkes SJM, Marie JP, Labar B. High dose (HD-AraC) vs standard dose cytosine arabinoside (SD-AraC) during induction and IL-2 vs observation after consolidation/autologous stem cell transplantation in patients with acute myelogenous leukemia (AML): final report of the AML-12 trial of EORTC and GIMEMA leukemia groups on the value of low dose IL-2 maintenance [abstract]. Blood 2011;118(21):117-8.
15. Benyunes MC, Massumoto C, York A, Higuchi CM, Buckner CD, Thompson J, et al. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 1993;12(2):159-63.
16. Brune L, Rowe JM, Buyse ME, Squifflet P, Castaigne S, Allard SE, et al. Six-year outcomes update from a randomized Phase 3 trial in AML: Durable effect of remission maintenance immunotherapy with histamine dihydrochloride and low-dose IL-2. Haematologica 2009;94(Suppl 2):340.
17. Ganser A, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML). Annals of Hematology 2000;79(1):30-5.
18. Hiddemann W, Unterhalt M, Kemper M, Schleyer E, Schonrock-Nabulsi P, Uharek L, et al. S-HAM salvage therapy in relapsed and refractory AML followed by interleukin 2 postremission therapy. Annals of Hematology 1994;68(Suppl 1):A9.
19. Meloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. The Cancer Journal from Scientific American 1997;3(Suppl 1):S43-7.
20. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Liu-Mares W, et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. Journal of Clinical Oncology 1998;16(3):914-9.
21. Stone RM, DeAngelo DJ, Janosova A, Galinsky I, Canning C, Ritz J, et al. Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. American Journal of Hematology 2008;83(10):771-7.
22. Treating patients with childhood acute myeloid leukaemia with interleukin-2. Ongoing study March 2005.
23. Alcalai R, Ben-Yehuda D, Ronen I, Paltiel O. Ethnicity and prognosis in acute myeloid leukemia. American Journal of Hematology 2003;72(2):127-34.
24. Aplenc R, Alonzo TA, Gerbing RB, Smith FO, Meshinchi S, Ross JA. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. Blood 2006;108(1):74-80.
25. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood 2006;107(9):3481-5.
26. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukanemias. French-American-British (FAB) cooperative group. British Journal of Haematology 1976;33(4):451-8.
27. Brune M, Hellstrand K. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. British Journal of Haematology 1996;92(3):620-6.
28. Brune M, Castaigne S, Catalano J, Gehlsen K, Ho AD, Hofmann W-K, et al. Improved leukaemia-free survival after post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized Phase III trial. Blood 2006;108(1):88-96.
29. Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. Journal of Clinical Oncology 2009;27(1):61-9.
30. Buyse M, Squifflet P, Lange BJ, Alonzo TA, Larson RA, Kolitz JE, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011;117(26):7007-13.
31. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. Journal of Clinical Investigation 1993;91(1):123-32.
32. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
33. Farag SS, George SL, Lee EJ, Baer M, Dodge RK, Becknell B, et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clinical Cancer Research 2002;8(9):2812-9.
34. Fierro MT, Laio X, Lusso P, Bonferroni M, Matera L, Cesano A, et al. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia 1988;2(1):50-4.
35. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108(10):3280-8.
36. Brozek J, Oxman A, Schünemann H. Grading of Recommendations Assessment, Development and Evaluation (GRADE). 3.2. Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group, 2008.
37. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999;17(12):3835-49.
38. Heitger A, Winklehner P, Obexer P, Eder J, Zelle-Rieser C, Kropshofer G, et al. Defective T-helper cell function after T-cell-depleting therapy affecting naive and memory populations. Blood 2002;99(11):4053-62.
39. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2010. Available from: http://seer.cancer.gov/csr/1975_2010/ (accessed 23 June 2013).
43. Johnson CS, Thurlow SM, Furmanski P. Lymphokine activated killer cell plus recombinant interleukin 2 therapy of erythroleukemia in mice. Leukemia 1989;3(2):91-6.
44. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113(18):4179-87.
45. Krug U, Lubbert M, Buchner T. Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?. Current Opinion in Hematology 2010;17(2):85-90.
46. Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, et al. Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for untreated paediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood 2008;111(3):1044-53.
47. Lauria F, Raspadori D, Rondelli D, Ventura MA, Foa R. In vitro susceptibility of acute leukaemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994;8(5):724-8.
48. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
49. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. The New England Journal of Medicine 1999;341(14):1051-62.
50. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
51. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, et al. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 1991;78(9):2182-7.
52. Maraninchi D, Vey N, Viens P, Stoppa AM, Archimbaud E, Attal M, et al. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leukemia and Lymphoma 1998;31(3-4):343-9.
53. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994;84(7):2158-63.
54. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
55. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
57. Romero AI, Thorén FB, Aurelius J, Askarieh G, Brune M, Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scandinavian Journal of Immunology 2009;70(3):194-205.
58. Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Wiernik PH, et al. Very poor survival of patients with AML who relapse after achieving a first complete remission: The Eastern Cooperative Oncology Group experience [abstract]. Blood 2005;106(11):546.
59. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
60. Stein AS, O'Donnell MR, Slovak ML, Snyder DS, Nademanee AP, Parker P, et al. Interleukin-2 after autologous stem-cell transplantation for adult patients with acute myeloid leukemia in first complete remission. Journal of Clinical Oncology 2003;21(4):615-23.
61. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Stoppa AM, Fossat C, Blaise D, Viens P, Brandely M, Pourreau CN, et al. Interleukin-2 induces chemotactic deficiency in patients with onco hematologic malignancies and autologous bone marrow transplantation. European Cytokine Network 1991;2(4):231-7.
63. Tajima F, Kawatani T, Endo A, Kawasaki H. Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia. Leukemia 1996;10(3):478-82.
64. Thoren FB, Romero AI, Brune M, Hellstrand K. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia. Expert Opinion on Biological Therapy 2009;9(9):1217-23.
65. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
66. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114(5):937-51.
67. Wheatley K, Brookes CL, Howman AJ, Goldstone AH, Milligan DW, Prentice AG, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. British Journal of Haematology 2009;145(5):598-605.
68. Willemze R, Suciu S, Mandelli F, Halkes SJM, Marie JP, Labar B, et al. Value of low dose IL-2 as maintenance following consolidation treatment or autologous transplantation in acute myelogenous leukemia (AML) patients aged 15-60 years who reached CR after high dose (HD-AraC) vs standard dose (SD-AraC) cytosine arabinoside during induction: results of the AML-12 trial of EORTC and GIMEMA Leukemia Groups [abstract]. Blood 2009;114(22):791.
69. Mao C, Huang YF, Yang ZY, Ye QL, Wu XY, Hu XF, Zhai ZM, Tang JL. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD010248]